SEATTLE, May 24, 2021, (MEDGADGET) — Global Hyperhidrosis Treatment Market: Overview
Hyperhidrosis is a dermatological condition, in which excessive sweating is experienced by the patient. It majorly affects the area around the face, armpit, hands, and feet. The sweating will either take place in a specific area i.e. either localized, or generalized. Further it is divided into two subtypes, namely primary axillary hyperhidrosis and secondary generalized hyperhidrosis. A few primary indicators for hyperhidrosis comprise wet palms, feet, or soles along with persistent sweating. Hyperhidrosis may be present since birth or can develop later. Severe symptoms of the disease may cause fungal or bacterial. Hyperhidrosis can be caused due to a number of reasons such as anxiety disorder, heart disease, obesity and infectious diseases such as tuberculosis, malaria, etc.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2800
Global Hyperhidrosis Treatment Market: Drivers
Major players are concentrating on developing latest products to treat hyperhidrosis, this is expected to augment growth of global hyperhidrosis treatment market. For instance, Dermira Inc., in October 2018, introduced Qbrexa cloth to treat primary axillary hyperhidrosis. The wipes consists of glycopyrronium, a drug which is anti-cholinergic, and is formulated for pediatrics (9 years old and above) as well as adults. The U.S. Food & Drug Administration (FDA) granted approval to it in June, 2018.
Moreover, GlaxoSmithKline, in December 2016, finished its clinical trials phase II study for Umeclidinium to treat hyperhidrosis. This study was aimed at evaluating the efficacy, tolerability and pharmacokinetics of the medication in patients diagnosed with primary axillary hyperhidrosis. It was found that within 15 days of treatment, sweat reduction was observed up to a minimum of 50% in nearly seven patients. Therefore, developments such as this are expected to support the global hyperhidrosis treatment market growth over the forecast period.
Direct Purchase the Hyperhidrosis Treatment Market Report 2021 @ https://www.coherentmarketinsights.com/insight/buy-now/2800
Acceptance of strategies including mergers, collaborations, and acquisitions major players is expected to drive growth of the global hyperhidrosis market. For instance, Brickell Biotech Inc., a pharmaceutical company in its clinical stage signed an agreement with a pharmaceutical company, Kaken Pharmaceutical Co., Ltd., for developing BBI-4000, in April 2015. It’s a topical anticholinergic used to treat hyperhidrosis. Therefore, agreements of such kind are expected to fuel growth of the global hyperhidrosis treatment market.
Global Hyperhidrosis Treatment Market: Regional Analysis
North America is expected to gain the largest share in the global hyperhidrosis market in the forecast period, owing to the presence of major players including Dermira Inc., Brickell Biotech Inc., among others. These leading players are concentrating on tailoring growth policies such as acquisitions, mergers, collaboration, partnership, and so on. For instance, Brickell Biotech, Inc., a pharmaceutical company in its clinical stage, in June 2019, affiliated with a biopharmaceutical company, Vical Inc. The motive of this merger was to develop novel approaches for treating hyperhidrosis along with other kinds of dermatological disorders.
Moreover, Asia Pacific region is expected to foresee notable growth in the global hyperhidrosis treatment market, due to rising frequency of hyperhidrosis in this region. As per the 2018 data of Department of Dermatology, Government Medical College (India), among 10,000 cases, around 320 were diagnosed with hyperhidrosis. Therefore, higher pervasiveness of hyperhidrosis can lead to rise in the demand for treatment; this is expected to fuel growth of the global hyperhidrosis treatment market.
Global Hyperhidrosis Treatment Market: Restraints
Side effects of the drugs may impede the growth of the global hyperhidrosis treatment market. For instance, a topical treatment for hyperhidrosis is drystol, which causes side effects including burning, mild itching, allergic reactions, and dizziness, severe burning, and swelling on the area applied. Therefore, adverse effects of such medications are likely to hinder the growth of the global hyperhidrosis treatment market.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2800
Global Hyperhidrosis Treatment Market: Key Players
Key players functioning in the global hyperhidrosis treatment market consists, Allergan plc, GlaxoSmithKline plc, Theravida Inc., Brickell Biotech, Inc., Kaken Pharmaceutical Co., Ltd., Revance Therapeutics, Inc., Dermira, Inc., Avanor Healthcare Ltd., Dr. August Wolff GmbH and Ulthera, Inc.
Global Hyperhidrosis Treatment Market: Taxonomy
By Drug Class
By Route of Administration
By Distribution Channel
- Hospital pharmacies
- Online pharmacies
- Retail pharmacies
- North America
- Latin America
- Middle East
- Asia Pacific
Have a Look at Related Research Insights: